# Endosense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/endosense

- Industry: Healthcare Specialists
- Headquarters: Geneva, Switzerland
- Website: www.endosense.com
- Total disclosed funding: $96M
- Latest round: Series C (Nov 27, 2012)
- Investors on record: 9

## About

Endosense develops innovative medical technology, specializing in creating advanced tools for minimally invasive procedures. Their focus is on enhancing patient safety and improving clinical outcomes in the field of electrophysiology.Endosense was founded in 2003 in Geneva, Switzerland, as a company dedicated to developing cutting-edge solutions for the healthcare industry. The company has undergone strategic changes, including a successful acquisition by St. Jude Medical on August 19, 2013, in a deal valued at USD 331 million. This acquisition included an upfront payment of USD 170 million along with potential milestone payments totaling USD 161 million. Endosense has completed a total of 5 deals throughout its operations, marking its presence as an attractive target for investment and innovation in the medical technology sector.Endosense specializes in the sale and leasing of premium domain names, facilitating secure transactions for businesses and individuals seeking to establish an online presence. Their core offerings encompass direct domain purchases, a Lease to Own option enabling clients to pay a monthly fee for a designated period, and the ability to make offers on listed domains. This approach allows businesses to secure memorable and relevant domain names that enhance their branding and visibility in the digital space, catering to a diverse client base in North America, Europe, and parts of Asia.Endosense generates revenue primarily through the sale and leasing of domain names. Their transaction structure includes immediate sales and a Lease to Own plan, where clients pay a monthly fee towards ownership. For instance, one listed domain is priced at USD 8,911 for outright purchase or USD 409 per month for leasing. The company's focus on secure and hassle-free payment transactions supports its revenue model, addressing the growing demand for premium domain names in the digital marketplace.Following its acquisition by St. Jude Medical in August 2013, Endosense is positioned for strategic growth within the medical device market. Plans include the development of new technologies aimed at enhancing patient safety in electrophysiology. Additionally, Endosense seeks to expand its operations in emerging markets, particularly in Asia and Latin America, by 2025. The funds from the recent acquisition will be utilized to support research and development initiatives, ensuring that Endosense remains at the forefront of medical innovation.

## Funding rounds

- Series C, Nov 27, 2012, $40M — Andera Partners, Gimv, NGN Capital, NeoMed, Ysios Capital Partners, Vi Partners, Initiative Capital Romandie, Sectoral Asset Management
- Series B, Sep 1, 2009, $36M — Andera Partners, Gimv, NeoMed, Ysios Capital Partners, Vi Partners, Initiative Capital Romandie, Sectoral Asset Management
- Series A, Nov 21, 2005, $20M — 3i, NeoMed

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Series A
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series A, Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B, Series C
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series B, Series C
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series B, Series C
- Initiative Capital Romandie — Series B, Series C
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B, Series C
- NGN Capital (https://capitalatlas.ai/funds/ngn-capital) — Series C